Dr. Llombart-Cussac on the CASCADE Study in Metastatic Breast Cancer

Antonio Llombart-Cussac, MD, PhD
Published: Friday, Oct 07, 2016



Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.

The overall goal of the study was to examine patients with metastatic breast cancer in "real-life" scenarios, as opposed to clinical trial settings, explains Llombart-Cussac. Oncologists believed that the patients in clinical trials were very well-selected and therefore did not represent an accurate population for treatment.

The results of this study strongly support the prioritization of the most active treatment options for the initial lines in order to produce the longest overall survival in patients with metastatic breast cancer.


Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.

The overall goal of the study was to examine patients with metastatic breast cancer in "real-life" scenarios, as opposed to clinical trial settings, explains Llombart-Cussac. Oncologists believed that the patients in clinical trials were very well-selected and therefore did not represent an accurate population for treatment.

The results of this study strongly support the prioritization of the most active treatment options for the initial lines in order to produce the longest overall survival in patients with metastatic breast cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x